GHRP-6 10 mg by Dragon Pharma

Dragon Pharma Original Formula

GHRP-6

GH Releasing Peptide-610 mg vial
Class GHRP — Original / Strongest Appetite
Half-Life ~15–60 minutes
GH Potency Moderate-High
Appetite Effect Pronounced (Strongest GHRP)
Reconstitution Bacteriostatic Water
Form Subcutaneous Vial
Availability: In Stock
$65.00
Quantity
Shipping
Wishlist

GHRP-6 — The Original GHRP with Strongest Appetite Stimulation by Dragon Pharma

GHRP-6 (Growth Hormone Releasing Peptide-6) is Dragon Pharma's formulation of the first synthetic GHRP at 10mg per vial — the original GHS-R1a agonist developed by Bowers et al. beginning in the early 1980s, predating the discovery of its endogenous ligand ghrelin by nearly two decades. GHRP-6 occupies a distinct position in the GHRP hierarchy: moderate-to-high GH stimulation combined with the most pronounced appetite stimulation of any GHRP — a profile that makes it specifically valuable for mass-building phases where hitting caloric targets is as important as GH elevation.

Also searched as: GHRP-6 10mg, GHRP 6 peptide, GHRP-6 appetite, GHRP-6 Dragon Pharma, growth hormone releasing peptide 6.

GHRP-6's Historical Significance — The First Synthetic Ghrelin Receptor Agonist

Understanding GHRP-6 requires appreciating its role in the history of GH research:

  • Cyril Bowers and colleagues at Tulane University first synthesised compounds capable of stimulating GH release independently of GHRH in the early 1980s — the compound that became GHRP-6 was among the first characterised synthetic GHRPs, published in research through 1984
  • At the time of GHRP-6's development, the receptor it activated was unknown — it was simply observed to stimulate GH through a novel pathway. It wasn't until 1996 that Howard et al. cloned the GHS-R1a receptor, and not until 1999 that Kojima et al. identified ghrelin as the endogenous ligand for this receptor
  • In other words: GHRP-6 was developed and studied for 15+ years before anyone knew what receptor it activated or that an endogenous hormone (ghrelin) existed for that receptor. GHRP-6 was effectively a pharmacological probe that revealed the existence of an entire hormonal axis
  • This historical context also explains GHRP-6's larger 10mg vial vs GHRP-2's 5mg — GHRP-6 is typically used at higher volumes per cycle due to its appetite-stimulating bulk-focused application

Why GHRP-6 Has the Strongest Appetite Effect

The appetite mechanism is GHRP-6's defining characteristic and is rarely explained accurately:

  • GHS-R1a is expressed throughout the body but the density and coupling efficiency varies significantly by tissue. In the gut and vagal afferent neurons — the primary pathway for hunger signalling from gut to brain — GHRP-6 has particularly strong activity compared to other GHRPs
  • Ghrelin (the endogenous GHS-R1a agonist) rises before meals and signals hunger. GHRP-6 more closely mimics ghrelin's peripheral gut activity than GHRP-2, Hexarelin or Ipamorelin — producing a more intense and longer-lasting hunger signal
  • The practical consequence: GHRP-6 injections frequently produce a compelling, sometimes overwhelming hunger within 20-30 minutes — users often plan injections to coincide with meal timing so the appetite peak aligns with eating
  • This appetite stimulation is simultaneously GHRP-6's primary advantage for mass building (assists with caloric surplus maintenance) and its limiting factor for cutting (pronounced hunger during caloric deficit can be counterproductive)

GHRP-6 in the Complete GHRP Comparison

Parameter GHRP-6 GHRP-2 Hexarelin Ipamorelin
Year developed Early 1980s (first GHRP) Later generation Later generation Latest generation
GH potency Moderate-High High Highest Moderate
Appetite stimulation Strongest of all GHRPs Mild-Moderate Mild None
Cortisol elevation Moderate Moderate Significant Minimal
Best application Mass building — appetite + GH Balanced GH with mild appetite Maximum GH short cycles Clean long-term GH
Clinical use Cancer cachexia research Japan diagnostic test Cardiac research Clinical trials ongoing
Vial size (Dragon Pharma) 10 mg 5 mg 5 mg Various

GHRP-6 in Clinical Research — Cancer Cachexia

GHRP-6's clinical research history beyond the GH stimulation studies:

  • Cancer cachexia (the profound weight loss and muscle wasting associated with advanced cancer) has been an area of GHRP-6 investigation specifically because of its combined GH-elevating and appetite-stimulating properties — addressing two of the primary cachexia drivers simultaneously
  • Multiple Phase I and II studies have investigated GHRP-6 for cachexia — the appetite stimulation that is a side effect in healthy users is a therapeutic objective in this context
  • This clinical research generated human safety and pharmacokinetic data relevant to performance users — confirming tolerability at doses above typical performance protocols

Effects and Benefits

  • Moderate-to-high GH pulse stimulation via GHS-R1a — meaningful GH elevation for anabolic and recovery effects
  • Strongest appetite stimulation of any GHRP — the primary differentiating feature; beneficial for mass phases
  • Combined GH + appetite effect for mass building — two mechanisms supporting caloric surplus simultaneously
  • Synergistic with GHRH analogues — 3-5× GH amplification with CJC-1295 or Tesamorelin
  • Historical clinical data from cachexia research — human safety profile beyond animal studies
  • No testosterone suppression — no PCT required

Dosage and Administration

Protocol Dose Timing Frequency
Mass building 100–300 mcg Before meals — appetite peak coincides with eating 2–3× daily
GH optimisation 100–200 mcg Fasted or pre-workout; before bed 2–3× daily

At 10mg per vial and 200mcg per injection dosed 2× daily, one vial provides 25 days of dosing. The larger 10mg vial versus GHRP-2's 5mg reflects GHRP-6's typical use at higher cumulative volume in mass-phase protocols. A practical GHRP-6 timing approach for mass building: inject 15-20 minutes before a planned large meal — the appetite peak arrives as food is available, making it much easier to consume a large meal. Reconstitute with bacteriostatic water. Store refrigerated at 2-8°C after reconstitution.

When to Choose GHRP-6 vs Other GHRPs

  • Choose GHRP-6 when: in a mass-building phase with a caloric surplus target; struggling to eat enough; wanting both GH stimulation and appetite support from a single compound; not concerned with hunger management
  • Choose GHRP-2 instead when: wanting higher GH potency without the pronounced appetite; in a maintenance or recomposition phase where hunger management matters
  • Choose Ipamorelin instead when: in a cutting phase; appetite suppression is important; long-term continuous protocol where clean cortisol profile matters
  • Choose Hexarelin instead when: maximum GH pulse amplitude is the goal for a defined 4-6 week cycle

Stacking GHRP-6

  • CJC-1295 no DAC — GHRH partner for synergistic GH amplification; inject simultaneously for 3-5× combined pulse
  • MK-677 alongside GHRP-6 — both stimulate GHS-R1a (MK-677 orally, GHRP-6 by injection) and both stimulate appetite; together they produce sustained GH elevation and significant appetite increase — the most aggressive oral+injectable GH/appetite stack for bulking

"GHRP-6 is the original synthetic GHRP — developed before its receptor was known and before ghrelin existed as a concept. Its pronounced appetite stimulation is not a side effect but a defining feature, making it the GHRP of choice for mass phases where hitting a caloric surplus is as critical as GH elevation."

Reconstitution and Storage

Reconstitute with bacteriostatic water — add slowly along the vial wall and swirl gently. Store reconstituted vial refrigerated at 2-8°C for up to 28 days. Never freeze.

Please log in to write review.

GHRP-6 was developed by Cyril Bowers and colleagues at Tulane University in the early 1980s — the first synthetic compound shown to stimulate GH release through a mechanism independent of GHRH. Critically, it was developed 15+ years before its receptor (GHS-R1a) was cloned in 1996 and nearly 20 years before ghrelin — the endogenous hormone for that receptor — was discovered in 1999. GHRP-6 was a pharmacological probe that effectively revealed the existence of the entire ghrelin/GHS-R1a hormonal axis through its observed effects.

GHS-R1a is expressed in the gut and vagal afferent neurons as well as the pituitary. GHRP-6's structure more closely mimics ghrelin's peripheral gut activity than GHRP-2, Hexarelin or Ipamorelin — producing more intense activation of the gut-to-brain hunger signalling pathway. The appetite effect typically peaks 20-30 minutes after injection and can be compelling — many users plan injections 15-20 minutes before meals to align the appetite peak with food availability. This is GHRP-6's most useful practical feature for mass-building phases.

GHRP-2 produces higher GH pulse amplitude than GHRP-6 at equivalent doses — GHRP-2 is the second most potent GHRP (behind Hexarelin) while GHRP-6 is moderate-to-high. If maximum GH output is the primary goal, GHRP-2 is the better choice. If combining GH stimulation with meaningful appetite support for a mass phase, GHRP-6's stronger appetite effect makes it the preferable option — it delivers good GH alongside the hunger stimulus that helps maintain a caloric surplus.

GHRP-6 is typically used in higher-volume mass-phase protocols where appetite stimulation is a deliberate goal alongside GH. Users often run GHRP-6 for extended mass cycles at 200-300mcg per injection 2-3× daily — consuming more total milligrams per cycle than a GHRP-2 protocol. The 10mg vial provides approximately 25-33 days at 200-300mcg/day dosing, suited to the extended bulk-focused use case. GHRP-2 at 5mg is similarly sized for its typical use pattern.

Generally not the first choice. GHRP-6's pronounced appetite stimulation is counterproductive during caloric restriction — fighting hunger while simultaneously injecting a compound that powerfully stimulates it adds unnecessary difficulty. For cutting phases where GH support is wanted without appetite complications, Ipamorelin (no appetite stimulation, clean profile) or GHRP-2 (mild-moderate appetite, higher GH potency) are better suited. GHRP-6's appetite effect can occasionally be leveraged during cuts where the user struggles to reach protein targets despite the deficit.

No — GHRP-6 acts exclusively on GHS-R1a receptors in the pituitary and periphery. It has no interaction with androgen receptors, testosterone, LH, FSH or the HPG axis. No testosterone suppression occurs and no post-cycle therapy is required after stopping GHRP-6.